Growth hormone deficiency in treated acromegaly

Gherardo Mazziotti, Paolo Marzullo, Mauro Doga, Gianluca Aimaretti, Andrea Giustina

Research output: Contribution to journalArticlepeer-review


Growth hormone deficiency (GHD) of the adult is characterized by reduced quality of life (QoL) and physical fitness, skeletal fragility, and increased weight and cardiovascular risk. Hypopituitarism may develop in patients after definitive treatment of acromegaly, but an exact prevalence of GHD in this population is still uncertain owing to limited awareness and the scarce and conflicting data available on this topic. Because acromegaly and GHD may yield adverse consequences on similar target systems, the final outcomes of some complications of acromegaly may be further affected by the occurrence of GHD. However, it is still largely unknown whether patients with post-acromegaly GHD may benefit from GH replacement. We review the diagnostic, clinical, and therapeutic aspects of GHD in adult patients treated for acromegaly.

Original languageEnglish
Pages (from-to)11-21
Number of pages11
JournalTrends in Endocrinology and Metabolism
Issue number1
Publication statusPublished - Jan 1 2015


  • Acromegaly
  • Growth hormone deficiency
  • IGF-1
  • Mortality
  • Neurosurgery
  • Radiotherapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)


Dive into the research topics of 'Growth hormone deficiency in treated acromegaly'. Together they form a unique fingerprint.

Cite this